ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Padeliporfin VTP therapy shows high efficacy with an 86.5% overall response rate and 73% complete response rate in low-grade UTUC. The therapy provides an organ-sparing alternative to ...

Panelist discusses how urologists can benefit from adopting newer treatment modalities like aqua ablation for BPH, emphasizing its growing popularity, ease of learning, and efficiency in improving ...

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant radiographic ...

Cytoreductive nephrectomy (CN) remains vital in mRCC management, with immune checkpoint inhibitors (ICI) reshaping treatment strategies and patient selection criteria. The SCREEN score offers superior ...

Paul E. Dato, MD, discusses how a 69-year-old Black man presented with metastatic hormone-sensitive prostate cancer, showing symptoms of fatigue, nocturia, back pain, and weight loss, with initial ...

Investigators found that benefits of treatments that are observed in trials also appear in the real world. A recent study examined the relationship between randomized controlled trials and real-world ...

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical ...

Merrill discusses the evolving non–muscle invasive bladder cancer treatment space. Expanded access programs (EAPs), such as a recently FDA-authorized EAP in which ImmunityBio is partnering with the ...

Enzalutamide plus talazoparib significantly extended overall survival vs enzalutamide alone in mCRPC. Data from the phase 3 TALAPRO-2 trial (NCT03395197) showed that the combination of enzalutamide ...